Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQH2929
- Development stage
- Phase 1
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
TQH2929 is a novel monoclonal antibody under development for the treatment of psoriasis, including generalized pustular psoriasis (GPP). The drug is being evaluated primarily for its safety, tolerability, pharmacokinetics (PK), and preliminary efficacy in both healthy adults and patients with GPP. While the precise mechanism of action has not been publicly disclosed as of June 2025, it is classified as an antipsoriatic monoclonal antibody. Clinical trials are ongoing in China to assess its potential benefits in immune-mediated skin diseases[1][2][3][4].
- Other names
- TQH2929TQH-2929TQH 2929
Beyond the preview
Go deeper on TQH2929.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQH2929.